CiMaas started in March 2015. The focus of CiMaas is the development of cellular immunotherapy for the treatment of cancer. The first product is a dendritic cell (DC) vaccine. DC are able to activate the immune system and as such coordinate the activity of other immune cells that are able to attack the tumour cells. CiMaas further works on Natural Killer cell and develops the practical protocols to expand NK cells for and in clinical applications. Currently, CiMaas is finalizing the translational activities to GMP compliant protocols and building its’ Quality Management system in the facility in Geleen.